Eagle Pharmaceuticals Inc (NASDAQ: EGRX) stock closed at $5.68 on 11/29/23 after a major decline of -31.0%. Moreover, exceptionally high trading volume at 999% of normal accompanied the decline. The stock has been extremely weak relative to the market over the last nine months and has declined -34.6% during the last week.
Current PriceTarget Research Rating
EGRX’s future returns on capital are forecasted to be above the cost of capital. Accordingly, the company is expected to continue to be a Value Builder.
Eagle Pharmaceuticals has a current Value Trend Rating of C (High Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Eagle Pharmaceuticals has a very high Appreciation Score of 96 but a poor Power Rating of 21, with the High Neutral Value Trend Rating the result.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment